Table 2.
Expression levels of miRNAs targeting i.a. TYMS mRNA in cancer
| miRNA | Level† | Cancers‡ | References |
|---|---|---|---|
| miR-192-5p | Down | CRC tissues | Zhao et al. (2020b) |
| Down | CRC cell lines (HCT116, SW480, RKO, HT29) | Zheng et al. (2019b) | |
| Down | CRC tissues (TNM stage II) | Braun et al. (2008) | |
| Up | ESCC tissues and four cell lines | Li et al. (2015c) | |
| Down | NSCLC: four cell lines (i.a. A549, H1299) | Zou et al. (2019) | |
| Down | BLCA tissues and five cell lines (i.a. T24) | Ji et al. (2018) | |
| Down | BRCA tissues, MCF-7 and MDA-MB-231 cell lines | Chen et al. (2019d) | |
| Down | HCC tissues | Wang et al. (2021h) | |
| Down | HCC tissues | Lian et al. (2016) | |
| Down | HCC tissues | Ge et al. (2015) | |
| Down | PCa: PC-3 and DU145 cell lines | Sun et al. (2016) | |
| miR-215-5p | Down | CRC tissues stages: III + IV vs I + II | Yan et al. (2020b) |
| Down | CRC tissues stages: II, III, IV vs I | Vychytilova et al. (2017) | |
| Down | CRC tissues stages: IV vs III vs II vs I | Chen et al. (2017c) | |
| Down | CRC tissues: liver metastasis vs without metastasis | Chen et al. (2017c) | |
| Down | CRC tissues and cell lines (SW480, HCT116, LoVo, HT29) | Chen et al. (2016) | |
| Down | CRC tissue stages: III–IV vs I–II | Chen et al. (2016) | |
| Down | CRC tissues (stage II) | Braun et al. (2008) | |
| Down | CRC tissues | Song et al. (2010) | |
| Up | CRC CSCs | Song et al. (2010) | |
| Up | GC tissues, TNM stage III–IV vs I–II | Chen et al. (2017e) | |
| Up | GC tissues, stage III/IV vs I/II | Li et al. (2016) | |
| Up | GC tissues | Deng et al. (2014b) | |
| Down | BRCA tissues | Wang et al. (2021i) | |
| Down | BRCA tissues, stage III–IV vs I–II, three cell lines | Gao et al. (2019) | |
| Down | BRCA tissues, cell lines (i.a. MDA-MB-231) | Yao et al. (2017) | |
| Down | BRCA tissues | Zhou et al. (2014a) | |
| Down | OVCA tissues and three cell lines | Ge et al. (2016) |
†”UP” or “down” in the level of a given miRNA: in cancerous tissues as compared to adjacent non-cancerous tissues (or to tissues of healthy individuals in cases of cervical and prostate cancers); one stage of cancer compared to another stage; cancer cell line compared to a normal epithelial cell line
‡Cancer tissues collected from patients and cancer cell lines of various types: BLCA bladder cancer, BRCA breast cancer (various molecular subtypes including triple-negative breast cancer TNBC), CeCa cervical cancer, CRC colorectal cancer, ESCC esophageal squamous cell carcinoma, GC gastric cancer, HCC hepatocellular carcinoma, LSCC laryngeal squamous cell carcinoma, NSCLC non-small cell lung cancer (including LUAD lung adenocarcinoma SqCLC squamous cell lung carcinoma), OVCA ovarian cancer, OSCC oral squamous cell carcinoma, PCa prostate cancer, PDAC pancreatic ductal adenocarcinoma